Know Cancer

or
forgot password

Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study


N/A
12 Years
N/A
Open (Enrolling by invite only)
Both
Granulomatosis With Polyangiitis, Microscopic Polyangiitis

Thank you

Trial Information

Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study


Inclusion Criteria:



1. Enrollment in the RAVE trial

2. Completion of RAVE Common Closeout Date visit

3. Informed consent

Exclusion Criteria:

1. Refusal to participate

2. Inability to comply with standard-of-care, including routine clinical visits and
testing.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Long-term safety of rituximab for the treatment of ANCA-associated vasculitis

Outcome Description:

To determine the long-term safety of rituximab for the treatment of ANCA-associated vasculitis (granulomatosis with polyangiitis (Wegener's granulomatosis) and microscopic polyangiitis).

Outcome Time Frame:

Four years

Safety Issue:

Yes

Authority:

United States: Institutional Review Board

Study ID:

ML27815

NCT ID:

NCT01586858

Start Date:

May 2012

Completion Date:

Related Keywords:

  • Granulomatosis With Polyangiitis
  • Microscopic Polyangiitis
  • Vasculitis
  • ANCA
  • Rituximab
  • Small vessel vasculitis
  • Vasculitis
  • Wegener Granulomatosis
  • Systemic Vasculitis
  • Microscopic Polyangiitis
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Name

Location

Johns Hopkins UniversityBaltimore, Maryland  21205
University of AlabamaBirmingham, Alabama  
Boston UniversityBoston, Massachusetts  02118
Duke UniversityDurham, North Carolina  27710
Hospital for Special SurgeryNew York, New York  10021
The Cleveland ClinicCleveland, Ohio  44195
Mayo Clinic FoundationRochester, Minnesota  55905